198 Applying Pharmacogenomics in Therapeutics40. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. (1990). Aninsertion/deletion polymorphism in the angiotensin I-converting enzyme gene accountingfor half the variance of serum enzyme levels. Journal of Clinical Investigation, 86:1343–1346.41. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. (1992).Evidence, from combined segregation and linkage analysis, that a variant of the angiotensinI-converting enzyme (ACE) gene controls plasma ACE levels. American Journalof Human Genetics, 51: 197–205.42. Bleumink GS, Schut AF, Sturkenboom MC, van Duijn CM, Deckers JW, Hofman A,Kingma JH, Witteman JC, Stricker BH. (2005). Mortality in patients with hypertensionon angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by theACE insertion/deletion polymorphism. Pharmacogenetics & Genomics, 15: 75–81.43. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. (2002).Pharmacogenetic approaches to hypertension therapy: Design and rationale for theGenetics of Hypertension Associated Treatment (GenHAT) study. PharmacogenomicsJournal, 2: 309–317.44. Harrap SB, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, Chapman N, et al.(2003). The ACE gene I/D polymorphism is not associated with the blood pressure andcardiovascular benefits of ACE inhibition. Hypertension, 42: 297–303.45. Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML,Jukema JW. (2011). A systematic review on pharmacogenetics in cardiovasculard isease: Is it ready for clinical application? European Heart Journal, 33: 165–175.46. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, Bertrand M,et al. (2010). Genetic determinants of treatment benefit of the angiotensin-convertingenzyme-inhibitor perindopril in patients with stable coronary artery disease. EuropeanHeart Journal, 31: 1854–1864.47. Redon J, Luque-Otero M, Martell N, Chaves F. (2004). Renin–angiotensin systemgene polymorphisms: Relationship with blood pressure and microalbuminuria intelmisartan-treated hypertensive patients. The Pharmacogenomics Journal, 5: 14–20.48. Ortlepp J, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. (2002). Variantsof the CYP11B2 gene predict response to therapy with candesartan. European Journalof Pharmacology, 445: 151–152.49. Huang CC, Chung CM, Hung SI, Leu HB, Wu TC, Huang PH, Lin SJ, Pan WH, Chen JW.(2011). Genetic variation in renin predicts the effects of thiazide diuretics. EuropeanJournal of Clinical Investigation, 41(8): 828–835. doi:10.1111/j.1365-2362.2011.02472.x.50. Nordestgaard BG, Kontula K, Benn M, Dahlöf B, de Faire U, Edelman JM, Eliasson E,et al. (2010). Effect of ACE insertion/deletion and 12 other polymorphisms on clinicaloutcomes and response to treatment in the LIFE study. Pharmacogenetics and Genomics,20(2): 77–85. doi: 10.1097/FPC.0b013e328333f70b.51. Beeks E. (2004). Adducin Gly460Trp polymorphism and renal hemodynamics inessential hypertension. Hypertension, 44: 419–423.52. Lynch A, Boerwinkle E, Davis B, Ford C, Eckfeldt J, Leiendecker-Foster C, Arnett D.(2008). Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovasculardisease outcomes in patients with hypertension. JAMA, 299: 296–307.53. Katz A. (1986). Pharmacology and mechanisms of action of calcium-channel blockers.Journal of Clinical Hypertension, 2: 28S–37S.54. Bremer T, Man A, Kask K, Diamond C. (2006). CACNA1C polymorphisms are associatedwith the efficacy of calcium channel blockers in the treatment of hypertension.Pharmacogenomics, 7: 271–279.55. Langaee T, Gong Y, Yarandi H, Katz D, Cooper-Dehoff R, Pepine C, Johnson J. (2007).Association of CYP3A5 polymorphisms with hypertension and antihypertensiveresponse to verapamil. Clinical Pharmacology & Therapeutics, 81: 386–391.
Drug Therapy of Cardiovascular Diseases19956. Pacanowski M, Gong Y, Cooper-Dehoff R, Schork N, Shriver M, Langaee T, Johnson J.(2008). Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomesin hypertension. Clinical Pharmacology & Therapeutics, 84: 715–721.57. Beitelshees A, Gong Y, Wang D, Schork N, Cooper-Dehoff R, Langaee T, Johnson J.(2007). KCNMB1 genotype influences response to verapamil SR and adverse outcomesin the International Verapamil SR/Trandolapril Study (INVEST). Pharmacogeneticsand Genomics, 17, 719–729.58. Aerssens J, Paulussen AD. (2005). Pharmacogenomics and acquired long QT syndrome.Pharmacogenomics, 6(3): 259–270.59. Li G, Cheng G, Wu J, Zhou X, Liu P, Sun C. (2013). Drug-induced long QT syndromein women. Advances in Therapy, 30: 793–802.60. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC,Beaune P, Bagot M. (1995). A slow acetylator genotype is a risk factor forsulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.Pharmacogenetics, 5: 255–258.61. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, et al.(2010) Reduced function CYP2C19 genotype and risk of adverse clinical outcomesamong patients treated with clopidogrel predominantly for PCI: A meta-analysis.JAMA 304: 1821–1830.62. Roden DM, Stein CM. (2009). Clopidogrel and the concept of high-risk pharmacokinetics.Circulation 119: 2127–2130.
Change language